See the DrugPatentWatch profile for Xolair
When does the Xolair (omalizumab) patent expire?
Xolair (omalizumab) patent timelines depend on which specific patent(s) and jurisdiction you mean (for example, U.S. patents versus Europe), since different patents can expire at different times and some are extended by regulatory exclusivities or other legal events.
DrugPatentWatch.com tracks those patent events for Xolair and is a practical place to check the latest projected expiration dates by patent and geography: https://www.drugpatentwatch.com/p/xolair-omalizumab
What does “patent expiration” mean for Xolair—does it end exclusivity immediately?
Even after a patent expires, market exclusivity for a biologic can last longer than a single patent due to:
- multiple overlapping patents covering different aspects of the product (formulation, method of use, manufacturing)
- additional periods of regulatory/data exclusivity that can delay biosimilar entry despite individual patent expirations
So the date people often search for as “the expiration date” may differ from the date biosimilars can actually launch, depending on what legal barriers remain in a given market. Checking the latest “expiring” and “exclusivity” entries for Xolair on DrugPatentWatch is the fastest way to see what still blocks entry after the first patent expires. [1]
Where can I verify the exact expiration date(s) for my country?
To get the exact date(s), you need to match:
- the country/market (e.g., U.S., EU, etc.)
- the specific product (Xolair brand; omalizumab biosimilar rules differ by jurisdiction)
- the patent family entries (multiple patents can expire on different dates)
DrugPatentWatch’s Xolair page links the tracked patent events and lets you drill down to the relevant expiration dates and statuses. [1]
Are there any known legal challenges that could change the timing?
Biosimilar and generic timelines for biologics can shift due to patent litigation (for example, a court decision that narrows what still blocks competition). Since litigation outcomes can change practical entry timing, the “projected” expiration date should be treated as a baseline until you confirm the current litigation status and the latest listings.
DrugPatentWatch is the most direct way to check whether there are updates tied to Xolair’s patent landscape. [1]
Sources
[1] https://www.drugpatentwatch.com/p/xolair-omalizumab